NUVL
Price
$81.08
Change
+$2.18 (+2.76%)
Updated
Sep 23 closing price
Capitalization
5.85B
43 days until earnings call
VRDN
Price
$19.56
Change
+$0.01 (+0.05%)
Updated
Sep 23 closing price
Capitalization
1.6B
55 days until earnings call
Interact to see
Advertisement

NUVL vs VRDN

Header iconNUVL vs VRDN Comparison
Open Charts NUVL vs VRDNBanner chart's image
Nuvalent
Price$81.08
Change+$2.18 (+2.76%)
Volume$324.8K
Capitalization5.85B
Viridian Therapeutics
Price$19.56
Change+$0.01 (+0.05%)
Volume$471.5K
Capitalization1.6B
NUVL vs VRDN Comparison Chart in %
Loading...
NUVL
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
VRDN
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
NUVL vs. VRDN commentary
Sep 24, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is NUVL is a StrongBuy and VRDN is a StrongBuy.

Interact to see
Advertisement
COMPARISON
Comparison
Sep 24, 2025
Stock price -- (NUVL: $81.08 vs. VRDN: $19.56)
Brand notoriety: NUVL and VRDN are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: NUVL: 72% vs. VRDN: 59%
Market capitalization -- NUVL: $5.85B vs. VRDN: $1.6B
NUVL [@Biotechnology] is valued at $5.85B. VRDN’s [@Biotechnology] market capitalization is $1.6B. The market cap for tickers in the [@Biotechnology] industry ranges from $97.36B to $0. The average market capitalization across the [@Biotechnology] industry is $1.91B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

NUVL’s FA Score shows that 0 FA rating(s) are green whileVRDN’s FA Score has 0 green FA rating(s).

  • NUVL’s FA Score: 0 green, 5 red.
  • VRDN’s FA Score: 0 green, 5 red.
According to our system of comparison, NUVL is a better buy in the long-term than VRDN.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

NUVL’s TA Score shows that 7 TA indicator(s) are bullish while VRDN’s TA Score has 4 bullish TA indicator(s).

  • NUVL’s TA Score: 7 bullish, 3 bearish.
  • VRDN’s TA Score: 4 bullish, 4 bearish.
According to our system of comparison, NUVL is a better buy in the short-term than VRDN.

Price Growth

NUVL (@Biotechnology) experienced а +3.51% price change this week, while VRDN (@Biotechnology) price change was +4.82% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +2.75%. For the same industry, the average monthly price growth was +7.78%, and the average quarterly price growth was +47.65%.

Reported Earning Dates

NUVL is expected to report earnings on Nov 06, 2025.

VRDN is expected to report earnings on Nov 18, 2025.

Industries' Descriptions

@Biotechnology (+2.75% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
NUVL($5.85B) has a higher market cap than VRDN($1.6B). NUVL YTD gains are higher at: 3.577 vs. VRDN (2.034). VRDN has higher annual earnings (EBITDA): -340.62M vs. NUVL (-362.01M). NUVL has more cash in the bank: 1.01B vs. VRDN (563M). VRDN has higher revenues than NUVL: VRDN (305K) vs NUVL (0).
NUVLVRDNNUVL / VRDN
Capitalization5.85B1.6B366%
EBITDA-362.01M-340.62M106%
Gain YTD3.5772.034176%
P/E RatioN/AN/A-
Revenue0305K-
Total Cash1.01B563M179%
Total DebtN/A21.3M-
FUNDAMENTALS RATINGS
VRDN: Fundamental Ratings
VRDN
OUTLOOK RATING
1..100
75
VALUATION
overvalued / fair valued / undervalued
1..100
94
Overvalued
PROFIT vs RISK RATING
1..100
85
SMR RATING
1..100
99
PRICE GROWTH RATING
1..100
45
P/E GROWTH RATING
1..100
100
SEASONALITY SCORE
1..100
18

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

TECHNICAL ANALYSIS
Technical Analysis
NUVLVRDN
RSI
ODDS (%)
N/A
N/A
Stochastic
ODDS (%)
Bearish Trend 1 day ago
78%
Bullish Trend 1 day ago
76%
Momentum
ODDS (%)
Bullish Trend 1 day ago
84%
Bearish Trend 1 day ago
90%
MACD
ODDS (%)
Bullish Trend 1 day ago
84%
Bearish Trend 1 day ago
81%
TrendWeek
ODDS (%)
Bullish Trend 1 day ago
82%
Bullish Trend 1 day ago
81%
TrendMonth
ODDS (%)
Bullish Trend 1 day ago
81%
Bullish Trend 1 day ago
83%
Advances
ODDS (%)
Bullish Trend 1 day ago
82%
Bullish Trend 1 day ago
81%
Declines
ODDS (%)
Bearish Trend 9 days ago
78%
Bearish Trend 10 days ago
85%
BollingerBands
ODDS (%)
Bearish Trend 1 day ago
85%
Bearish Trend 1 day ago
90%
Aroon
ODDS (%)
Bullish Trend 1 day ago
83%
Bullish Trend 1 day ago
86%
View a ticker or compare two or three
Interact to see
Advertisement
NUVL
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
VRDN
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
VIVIX72.620.15
+0.21%
Vanguard Value Index I
ASMOX23.12-0.05
-0.22%
AQR Small Cap Momentum Style I
VVSGX17.55-0.10
-0.57%
VALIC Company I Small Cap Growth
LMPRX103.83-0.72
-0.69%
ClearBridge Growth R
NESYX65.81-0.53
-0.80%
Natixis US Equity Opportunities Y

NUVL and

Correlation & Price change

A.I.dvisor indicates that over the last year, NUVL has been loosely correlated with XENE. These tickers have moved in lockstep 59% of the time. This A.I.-generated data suggests there is some statistical probability that if NUVL jumps, then XENE could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To NUVL
1D Price
Change %
NUVL100%
+2.76%
XENE - NUVL
59%
Loosely correlated
-0.11%
CGON - NUVL
58%
Loosely correlated
-0.92%
IDYA - NUVL
57%
Loosely correlated
+0.04%
RVMD - NUVL
57%
Loosely correlated
-0.46%
NRIX - NUVL
57%
Loosely correlated
-2.25%
More

VRDN and

Correlation & Price change

A.I.dvisor indicates that over the last year, VRDN has been loosely correlated with SYRE. These tickers have moved in lockstep 58% of the time. This A.I.-generated data suggests there is some statistical probability that if VRDN jumps, then SYRE could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To VRDN
1D Price
Change %
VRDN100%
+0.05%
SYRE - VRDN
58%
Loosely correlated
+4.77%
CRNX - VRDN
56%
Loosely correlated
+6.35%
NUVL - VRDN
55%
Loosely correlated
+2.76%
OCUL - VRDN
52%
Loosely correlated
+0.41%
BEAM - VRDN
52%
Loosely correlated
-2.79%
More